Spiridon
Spiridon Kintzios, Athens GR
Patent application number | Description | Published |
---|---|---|
20090170068 | Molecular Identification Through Membrane-Engineered Cells - The present invention relates to the development of analytical devises based on one or more cells (cellular biosensors) the surface of which has been modified by the artificial insertion of molecules that can react specifically with analytes under determination. These receptor molecules may be proteins (such as enzymes, antigens or antibodies), nucleic acids, carbohydrates, lipids or belong to any other chemical group able to react specifically with target molecules (< | 07-02-2009 |
Spiridon Pachnis, Vrilisia GR
Patent application number | Description | Published |
---|---|---|
20130267297 | METHODS AND SYSTEMS FOR CONDUCTING LOTTERY GAMES WITH PORTABLE DEVICES ENABLED FOR NEAR FIELD COMMUNICATION (NFC) - In some embodiments, the instant invention provides for a computer system that includes a processor executing the code to: receive an indication indicating that a player desires to participate in a lottery game based on a near field communication (NFC) between a mobile device of the player and a first game piece associated with the lottery game conducted by a game conducting authority; conduct a drawing in accordance with rules of the lottery game; receive an indication identifying an action performed by the player in accordance with the rules of the lottery game where the action is based on: i) a result of the drawing and ii) NFC communication between the mobile device of the player and a second game piece associated with the lottery game; and distribute a prize to player in accordance with the rules of the lottery game. | 10-10-2013 |
20140206426 | METHODS AND SYSTEMS FOR CONDUCTING LOTTERY GAMES WITH PORTABLE DEVICES ENABLED FOR NEAR FIELD COMMUNICATION (NFC) - In some embodiments, the instant invention provides for a computer system that includes a processor executing the code to: receive an indication indicating that a player desires to participate in a lottery game based on a near field communication (NFC) between a mobile device of the player and a first game piece associated with the lottery game conducted by a game conducting authority; conduct a drawing in accordance with rules of the lottery game; receive an indication identifying an action performed by the player in accordance with the rules of the lottery game where the action is based on: i) a result of the drawing and ii) NFC communication between the mobile device of the player and a second game piece associated with the lottery game; and distribute a prize to player in accordance with the rules of the lottery game. | 07-24-2014 |
Spiridon Papapetropoulos, Auburndale, MA US
Patent application number | Description | Published |
---|---|---|
20100298438 | GENE EXPRESSION PROFILING OF PARKINSON'S DISEASE - The present invention identifies the changes in gene expression associated with Parkinson's Disease by examining multiregional gene expression from normal brain and brain of Parkinson's Disease. The present also identifies the changes in gene expression associated with Parkinson's Disease by examining the expression of genes from normal blood and from the blood of patients with Parkinson's Disease. In another aspect, the present invention identifies expression profiles which serve as useful diagnostic markers as well as markers that can be used to monitor disease states, disease progression, drug toxicity, drug efficacy and drug metabolism. | 11-25-2010 |
Spiridon Spireas, Newton, PA US
Patent application number | Description | Published |
---|---|---|
20100099723 | BIOAVAILABLE COMPOSITIONS OF METAXALONE AND PROCESSES FOR PRODUCING THE SAME - Pharmaceutical compositions comprising metaxalone which demonstrate improved dissolution and bioavailability characteristics compared to the commercially available product, and methods of producing them are provided. In a preferred embodiment, a dosage form comprising metaxalone and at least one inactive powder excipient is bioequivalent to its commercially available counterpart (Skelaxin® 400-mg tablets) after oral administration to fasting or non-fasting human subjects, while at the same time displaying faster drug dissolution rates than the Skelaxin® tablets as demonstrated from three different dissolution tests. In another preferred embodiment, a dosage form comprising metaxalone, at least one inactive powder excipient and a nonvolatile liquid is significantly more bioavailable than the commercially available Skelaxin® 400-mg tablets after oral administration to fasting human subjects. | 04-22-2010 |
20110124694 | BIOAVAILABLE COMPOSITIONS OF METAXALONE AND PROCESSES FOR PRODUCING THE SAME - Pharmaceutical compositions comprising metaxalone which demonstrate improved dissolution and bioavailability characteristics compared to the commercially available product, and methods of producing them are provided. In a preferred embodiment, a dosage form comprising metaxalone and at least one inactive powder excipient is bioequivalent to its commercially available counterpart (Skelaxin® 400-mg tablets) after oral administration to fasting or non-fasting human subjects, while at the same time displaying faster drug dissolution rates than the Skelaxin® tablets as demonstrated from three different dissolution tests. In another preferred embodiment, a dosage form comprising metaxalone, at least one inactive powder excipient and a nonvolatile liquid is significantly more bioavailable than the commercially available Skelaxin® 400-mg tablets after oral administration to fasting human subjects. | 05-26-2011 |
Spiridon Spireas, Newtown, PA US
Patent application number | Description | Published |
---|---|---|
20080221156 | STABLE FORMULATIONS OF ACE INHIBITORS, AND METHODS FOR PREPARATION THEREOF - The present invention provides stable formulations of ACE inhibitors, especially enalapril maleate, that can be manufactured in a time efficient, cost effective manner. Such formulations can be prepared simply and on a large industrial scale. The present invention also provides methods for the preparation of stable formulations of ACE inhibitors, especially enalapril maleate. | 09-11-2008 |
Spiridon Spireas, New Hope, PA US
Patent application number | Description | Published |
---|---|---|
20120196834 | Highly stable compositions of orally active nucleotide analogues or orally active nucleotide analogue prodrugs - Disclosed are highly stable compositions having outstanding storage stability and/or demonstrating exceptional resistance to aqueous solution degradation, the composition including an orally active nucleotide analogue or an orally active nucleotide analogue prodrug, which is orally bioavailable, such as adefovir dipivoxil and tenofovir disoproxil. For example, when a composition of the invention is stored for 1 month or for 18 months at 25° C. and 60% relative humidity, its orally active nucleotide analogue or orally active nucleotide analogue prodrug degrades to provide a composition containing no more than 0.2% or no more than 0.7% by weight of a less orally bioavailable impurity, respectively. Also disclosed are a container/closure package system including the composition and a package insert and methods of manufacturing the composition and treating a patient for a disease or condition, for example, a viral disease or cancer, with the use of the composition. | 08-02-2012 |
20130245082 | BIOAVAILABLE COMPOSITIONS OF METAXOLONE COMPRISING NONVOLATILE LIQUIDS AND PROCESSES FOR PRODUCING THE SAME - Pharmaceutical compositions comprising metaxalone which demonstrate improved dissolution and bioavailability characteristics compared to the commercially available product, and methods of producing them are provided. In a preferred embodiment, a dosage form comprising metaxalone and at least one inactive powder excipient is bioequivalent to its commercially available counterpart (Skelaxin® 400-mg tablets) after oral administration to fasting or non-fasting human subjects, while at the same time displaying faster drug dissolution rates than the Skelaxin® tablets as demonstrated from three different dissolution tests. In another preferred embodiment, a dosage form comprising metaxalone, at least one inactive powder excipient and a nonvolatile liquid is significantly more bioavailable than the commercially available Skelaxin® 400-mg tablets after oral administration to fasting human subjects. | 09-19-2013 |
20130245083 | METHODS OF TREATMENT WITH BIOAVAILABLE COMPOSITIONS OF METAXALONE COMPRISING NONVOLATILE LIQUIDS - Pharmaceutical compositions comprising metaxalone which demonstrate improved dissolution and bioavailability characteristics compared to the commercially available product, and methods of producing them are provided. In a preferred embodiment, a dosage form comprising metaxalone and at least one inactive powder excipient is bioequivalent to its commercially available counterpart (Skelaxin® 400-mg tablets) after oral administration to fasting or non-fasting human subjects, while at the same time displaying faster drug dissolution rates than the Skelaxin® tablets as demonstrated from three different dissolution tests. In another preferred embodiment, a dosage form comprising metaxalone, at least one inactive powder excipient and a nonvolatile liquid is significantly more bioavailable than the commercially available Skelaxin® 400-mg tablets after oral administration to fasting human subjects. | 09-19-2013 |